Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luseogliflozin - Taisho Pharmaceutical

Drug Profile

Luseogliflozin - Taisho Pharmaceutical

Alternative Names: Lusefi; Luseogliflozin hydrate; TS-071

Latest Information Update: 18 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taisho Pharmaceutical
  • Class Antihyperglycaemics; Glucosides; Phenyl ethers; Small molecules; Sugar alcohols; Sulfides
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 09 Apr 2019 Taisho Toyama Pharmaceutical terminates a clinical trial for Type 2 diabetes mellitus in Japan (UMIN000032005)
  • 26 Jan 2019 Taisho Toyama Pharmaceutical completes a clinical trial for Type 2 diabetes mellitus in Japan (UMIN000026887)
  • 30 Aug 2018 Taisho Toyama Pharmaceutical initiates enrolment in the COMET trial for Type II diabetes mellitus in Japan (UMIN000033961)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top